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ABSTRACT
Introduction: Cataract is one of the leading causes of
low vision in the westernised world, and cataract
surgery is one of the most commonly performed
operations. Laser platforms for cataract surgery are
now available, the anticipated advantages of which are
broad and may include better visual outcomes through
greater precision and reproducibility, and improved
safety. FACT is a randomised single masked non-
inferiority trial to establish whether laser-assisted
cataract surgery is as good as or better than standard
manual phacoemulsification.
Methods and analysis: 808 patients aged 18 years
and over with visually significant cataract will be
randomised to manual phacoemulsification cataract
surgery (standard care) or laser-assisted cataract
surgery (intervention arm). Outcomes will be measured
at 3 and 12 months after surgery. The primary clinical
outcome is uncorrected distance visual acuity (UDVA,
logMAR) at 3 months in the study eye recorded by an
observer masked to the trial group. Secondary
outcomes include UDVA at 12 months, corrected
distance visual acuity at 3 and 12 months,
complications, endothelial cell loss, patient-reported
outcome measures and a health economic analysis
conforming to National Institute for Health and Care
Excellence standards.
Ethics and dissemination: Research Ethics
Committee Approval was obtained on 6 February 2015,
ref: 14/LO/1937. Current protocol: v2.0 (08/04/2015).
Study findings will be published in peer-reviewed
journals.
Trial registration number: ISRCTN: 77602616.
INTRODUCTION
Cataract is the leading cause of blindness in
the world,1 and one of the leading causes of
low vision in the UK.2 Cataract surgery is the
most commonly performed operation by the
UK National Health Service (NHS) with
around 330 000 cataract operations per-
formed per year in England.3 The current
surgical method used for over 99%4 cases
was ﬁrst introduced into routine clinical
practice over 20 years ago and uses ultra-
sound (phacoemulsiﬁcation) to help break
up the cataract.
After cataract surgery, for eyes without
ocular copathology, 51% and 95% achieve
visual acuities of 0.00 and 0.30 logMAR
respectively;3 which are those perceived as
normal vision, and the minimum standard
for driving in the UK. Although cataract
Strengths and limitations of this study
▪ This is the first randomised multicentre UK trial
of laser-assisted cataract surgery compared to
manual phacoemulsification cataract surgery,
recruiting 808 patients over 18 months with a
12-month follow-up period.
▪ Outcome measures include visual outcomes,
complications, visual function and quality of life
measurements.
▪ The primary outcome measure is uncorrected
distance visual acuity at 3 months postopera-
tively and will be recorded by masked
optometrists.
▪ The trial findings will help inform National Health
Service providers, commissioners, patients and
ophthalmologists about the effectiveness and
cost-effectiveness of these two methods of cata-
ract surgery.
▪ A high recruitment rate will be required for the
trial to complete on schedule.
Day AC, et al. BMJ Open 2015;5:e010381. doi:10.1136/bmjopen-2015-010381 1
Open Access Protocol
surgery is a relatively safe operation, serious complica-
tions that may affect recovery and are associated with
poorer long-term outcomes occur in 2% operations.3
Posterior capsule rupture/vitreous loss (PCR/VL) is
the most frequently occurring serious complication
and is associated with an eight times higher risk of
postoperative endophthalmitis and a 42 times higher
risk of undergoing retinal detachment surgery within
3 months.3 The surgical learning curve for phacoemul-
siﬁcation is associated with complications, with a 3.7
and 1.6 times higher risk of PCR/VL for junior surgi-
cal trainees and senior surgical trainees, respectively.5
In cases with PCR/VL, one-third of patients still have
symptoms about their eye and vision 3.5 years after
surgery.6
Laser platforms for cataract surgery are currently avail-
able from ﬁve manufacturers. They can make the
corneal incisions, open the lens capsule and fragment
the cataract in 1 min, leaving only removal of lens frag-
ments and insertion of the lens implant to be per-
formed by the surgeon. The potential advantages are
broad and may include better visual outcomes through
greater precision and improved safety. These systems are
expensive, however costs may be mitigated by fewer com-
plications and improved outcomes. The absence of
robust evidence supporting the safety and efﬁcacy of
laser-assisted surgery from large randomised controlled
trials was highlighted in a review article7 and by the
National Institute of Health Research Horizon Scanning
Centre. The topic is a research priority as identiﬁed by
the national James Lind Alliance Sight Loss and Vision
Priority Setting Partnership (see http://www.
ﬁghtforsight.org.uk/sightlosspsp). A 1050 patient multi-
centre randomised economic evaluation is currently
underway in France with planned primary completion in
July 2015.8 To date, data from large comparative case
series suggest visual outcomes from laser cataract surgery
are similar to, or possibly better than, those from
manual phacoemulsiﬁcation.9 10
Trial objectives and design
The aim of this multicentre, single-masked randomised
controlled non-inferiority trial is to establish whether
laser-assisted cataract surgery is as good as or better than
standard surgery. The trial will help inform NHS service
providers, commissioners, patients and ophthalmologists
about the effectiveness and cost-effectiveness of these
two methods of cataract surgery.
The hypotheses being tested are that those rando-
mised to laser-assisted cataract surgery will have post-
operative visual acuities (uncorrected and corrected
distance visual acuity, UDVA and CDVA respectively) as
good as or better than those randomised to standard
care and improvements in endothelial cell loss, self-
reported visual function (assessed by the Catquest-SF9
questionnaire11) and EQ-5D quality of life score.12
Population: 808 patients with visually symptomatic cataract
(404 per arm).
Intervention: Laser-assisted cataract surgery.
Control: Standard phacoemulsiﬁcation cataract surgery.
Outcomes: visual acuity, visual function, refractive out-
comes, complications including endothelial cell loss and
cost-effectiveness.
METHODS
Study setting
The study sites are high volume NHS day care surgery
units that see large numbers of patients for routine cata-
ract surgeries and therefore have a sufﬁciently large
pool of patients to recruit successfully to a large rando-
mised study. These sites have access to the laser equip-
ment and offer a realistic NHS scenario.
Eligibility criteria
Inclusion criteria
Patients must meet all of the following criteria at the
time of randomisation to be eligible for recruitment:
▸ Adult aged 18 or over with visual symptoms attributed
by the examining ophthalmologist to the presence of
cataract in one or both eyes.
▸ Willing to attend for follow-up 3 and 12 months after
cataract surgery in the ﬁrst eye.
▸ Sufﬁciently ﬂuent in English for informed consent
and self-completion of the health state
questionnaires.
▸ The postoperative intended refractive target in the
study eye is within ±0.5 dioptres of emmetropia (ie,
the postoperative refractive target is good distance
vision).
The study eye is deﬁned as the ﬁrst eye to undergo
cataract surgery in the trial. This is chosen by the
patient in discussion with the surgeon. In those requir-
ing bilateral cataract surgery, the same intervention will
be offered for both eyes unless the patient wishes
otherwise.
In addition to the above, trial exclusion criteria include
any of the following:
▸ Corneal, ring and/or inlay implants, severe corneal
opacities, corneal abnormalities, signiﬁcant corneal
oedema and diminished aqueous clarity that is likely
to obstruct the optical coherence tomography
imaging of the anterior lens.i
▸ Descemetocele with impending corneal rupture.i
▸ Subluxed crystalline lens.i
▸ Poor pupil dilation that is expected to require surgi-
cal iris manipulation.
▸ Patient unable to give consent or attend follow-up
assessments.
▸ Patient unable to be positioned for surgery.i
▸ Scheduled for combined surgery, for example, cata-
ract and trabeculectomy.
iContraindication to use of the AMO Catalys cataract surgery laser,
from operator manual version DC-03013-01, Rev B, 02/2014.
2 Day AC, et al. BMJ Open 2015;5:e010381. doi:10.1136/bmjopen-2015-010381
Open Access
▸ Any clinical condition that the investigator considers
would make the patient unsuitable to take part in the
trial.
Interventions
Standard care/control arm: manual phacoemulsification
cataract surgery
This is the standard method of cataract surgery at par-
ticipating trial sites.
Typically this will involve topical or local anaesthesia
(with or without concurrent sedation depending on
patient or surgeon preference). The eye to undergo
cataract surgery will be dilated according to standard
local unit practice.
Following local standard surgical checks (WHO guide-
lines), the patient will be randomised before being trans-
ferred to the anaesthetic room or direct to the
operating theatre where the intended anaesthetic is
given.
Phacoemulsiﬁcation cataract surgery will then be per-
formed according to local standard practice and the
study operating manual. A plan for astigmatism will be
made prior to randomisation. Postoperative care includ-
ing postoperative eye drops will be as per standard unit
practice for cataract surgery.
The surgery start time will be deﬁned as application of
antiseptic solution to the periocular region by the oper-
ating surgeon following the ﬁnal patient check. The
surgery end time will be deﬁned as the time of removal
of the surgical drape.
Intervention arm: laser-assisted cataract surgery
Patients undergoing laser-assisted cataract surgery will be
prepared for surgery in the same way as those in the
standard care arm.
The patient will be transferred to the laser room prior
to the operating theatre, or to the operating theatre if
the laser platform is sited there. If a depot pellet has
been used for dilation, this will be removed at this stage.
Anaesthetic eye drops will be administered, the laser
interface placed in contact with the eye with the patient
lying down, the interface is docked to the laser platform,
the eye is scanned by the integral guidance and the
laser treatment delivered. The laser docking and treat-
ment delivery will be in accordance with the laser manu-
facturer’s recommended procedure as detailed in the
relevant operating manual.
The laser will be used to perform capsulotomy (typic-
ally 4.8–5.5 mm diameter), lens fragmentation and
corneal incisions including astigmatic keratotomies. A
recommended nomogram will be provided for planning
of the astigmatic keratotomies.
Following laser delivery, additional dilating drops will
be administered. The patient will be transferred to the
operating theatre if applicable and the remainder of the
care pathway is as per standard care with the obvious
exception that the surgical steps completed by laser do
not need to be performed by the surgeon.
Where the laser treatment cannot be performed for
whatever reason following randomisation to laser-assisted
cataract surgery (eg, unable to dock, laser machine
fault, etc) patients will undergo surgery in accordance to
that for standard care.
Astigmatism correction
All surgeons will be asked to describe their planned
method of attempted astigmatism correction prior to
surgery (including femtosecond laser astigmatic keratot-
omy for those randomised to laser).
Surgeon eligibility
Any ophthalmologists who routinely perform cataract
surgery at their respective trial sites and who have com-
pleted at least 10 supervised laser-assisted cataract
surgery operations will be able to perform surgery for
the laser-assisted or standard phacoemulsiﬁcation trial
arms.
Outcome measures
Primary outcome
▸ Uncorrected distance visual acuity (UDVA, logMAR)
at 3 months following surgery in the study eye mea-
sured using a standard Early Treatment Diabetic
Retinopathy Study (ETDRS) chart at a starting dis-
tance of 4 m.
Secondary outcomes
▸ UDVA at 12 months.
▸ CDVA, logMAR at 3 and 12 months in the study eye
(ETDRS logMAR chart at a starting distance of
4 m).
▸ Ocular complications within 3 and 12 months in the
study eye. A complication will be deﬁned as any event
that causes unintentional injury to an ocular
structure, or requires additional treatment, or has a
negative effect on a patient’s health or eyesight.
▸ Uncorrected and corrected visual acuity and compli-
cations in the second eye (for those with bilateral cat-
aracts), and with both eyes open at 3 and 12 months
(after surgery on the ﬁrst eye).
▸ Refractive error (spherical equivalent) within 0.5 and
within 1 dioptre of intended refractive outcome for
each eye.
▸ Quality of life as measured by the EQ-5D-3 L
questionnaire+vision bolt-on question (EQ-5DV) at
6 weeks, 3, 6 and 12 months.12
▸ Patient-reported vision health status using Catquest–
9SF,11 a Rasch validated instrument at 6 weeks, 3, 6
and 12 months.
▸ Cost-utility analysis reported as the incremental cost-
effectiveness ratio and cost-effectiveness acceptability
curves.
▸ Corneal endothelial cell count change at 3 and
12 months.
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Participant timeline
This can been seen in summary trial participant path-
ways table 1 and ﬁgure 1.
Trial duration
The study will take 30 months. Patient recruitment will
take place over the ﬁrst 18 months, and collection of the
data will continue for a further 12 months. The trial will
be considered closed when the last patient has reached
this time-point, all data is complete and all data queries
have been resolved. The REC will be notiﬁed within
90 days of the end of the trial and sent a summary
report of the research within 12 months of the end of
the trial.
Sample size
The primary clinical outcome is UDVA (logMAR) at
3 months in the study eye recorded by an optometrist or
technician masked to the trial group. A change in visual
acuity of 1 line of the chart is considered to be clinically
important. One logMAR line is 5 letters (each letter is
0.02 logMAR) and the test-retest variability is reported as
about 0.07 logMAR on letter-by-letter scoring.13 14 If
there is truly no difference in mean logMAR between
the two groups, then 432 patients (216 per group)
would provide 90% power to be sure that a 95% two-
sided CI would exclude the non-inferiority limit of 0.1
logMAR, assuming a common SD of 0.32. The SD is
from the Royal College of Ophthalmologists’ National
Ophthalmic Database UDVA data.3
However, although treatment is delivered on an indi-
vidual basis, each patient cannot be assumed to generate
independent information since they will be clustered
within surgeons. To take account of clustering by
surgeon (ie, the variation between surgeons in the treat-
ment effect) the sample size must be increased by an
inﬂation factor f=1+(m−1)×p. Assuming a total of 16 sur-
geons contribute and an average cluster size (m) of 50
(patients/surgeon) and an estimated ICC (p) of 0.012,
this yields an f of 1.59. A total of 688 patients (344 per
group) would enable the trial to take account of cluster-
ing by surgeon. To allow for an anticipated 15% dropout
rate (the mean age of patients undergoing cataract
surgery is 75 years old and many have signiﬁcant sys-
temic comorbidities) the total sample size required is
808 patients (404 per group).
Recruitment plan
All patients presenting to the recruitment centres with
visually signiﬁcant cataract who have elected to undergo
cataract surgery will be considered for enrolment. All
potential participants will be provided in advance with a
copy of the trial participant information sheet (see
online supplementary ﬁles for model copy of the trial
participant information).
Eligible patients will be identiﬁed by an ophthalmolo-
gist at the time of listing for cataract surgery and if
willing to join the study, informed consent will be
obtained and physical baseline measurements taken
after standard clinic listing and surgical consent for cata-
ract surgery by a trained member of the trial team. All
patients will be given as much time as they require and
offered separate alternative day enrolment appointments
(see online supplementary ﬁles for model copy of the
trial consent form).
Randomisation and allocation
Patients will be randomised to laser-assisted cataract
surgery or manual phacoemulsiﬁcation cataract surgery
(standard care) in equal proportions. Randomisation
will be performed by a member of the trial team on the
day of surgery and as close to the time of surgery as pos-
sible. A web-based randomisation application will be
used (https://www.sealedenvelope.com/uclctu/). The
randomisation algorithm will use treatment centre,
surgeon and one or both eyes eligible as minimisation
stratiﬁers.
Masking
Owing to the nature of the intervention, neither the
trial participants nor the treating clinician will be
masked to the treatment allocation.
To ensure masking of the outcomes data; visual acuity,
refraction, corneal measurements and endothelial cell
count measures at 3 and 12 months follow-up visits will
be performed by a trial optometrist or technician
without reference to previous patient medical notes or
trial case report forms. After these measures have been
completed, complications data will be collected by
patient medical notes review, for which masking is not
possible. Each site will be responsible for putting into
place a procedure to ensure the optometrist is kept
masked at all times, and will remind each patient not to
reveal their treatment to the optometrist at these two
visits.
Withdrawal
Patients may withdraw at any time. All withdrawals from
randomised treatment will be reported. The investigator
may withdraw patients from the study in the event of
intercurrent illness, AEs, SAEs, protocol violations,
administrative or other reasons. All data will be analysed
on an intention-to-treat basis.
Data management
All study data will be managed as detailed in the full
trial protocol and in accordance with the UK Data
Protection Act 1998. The trial database and coding
frames have been developed by the Clinical Trial
Manager in conjunction with CCTU. The database soft-
ware provides a number of features to help maintain
data quality, including; maintaining an audit trail, allow-
ing custom validations on all data, allowing users to raise
data query requests and search facilities to identify valid-
ation failure/ missing data.
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Table 1 Schedule for data collection and visits
Normal Baseline Allocation Treatment Follow-up
Prior to
enrolment
Prior to
surgery Surgery
Standard non-study
postoperative visit
6 weeks
(by post)
Visit 1:
3 months
6 months
(by post)
Visit 2:
12 months
Medical and ocular history ✓ ✓
Consent for cataract surgery ✓
Informed consent and eligibility screening ✓
Identification of study eye ✓
Visual acuity: UDVA, pinhole, +/− glasses
(Snellen)
✓ ✓* ✓
Visual acuity (logMAR) with usual method
of correction
✓
Visual acuity: UDVA† and CDVA‡
(logMAR) each eye and binocular
✓ ✓
Subjective refraction ✓ ✓
Ocular biometry ✓
Pentacam corneal topography ✓§ ✓ ✓ ✓
Optical coherence tomography (OCT) ✓§ ✓ ✓§ ✓ ✓
Inclusion/exclusion criteria ✓ ✓
Catquest-9SF questionnaire ✓ ✓ ✓ ✓ ✓
EQ-5D-3L+vision bolt-on question
(EQ-5DV)
✓ ✓ ✓ ✓ ✓
CSRI** ✓ ✓ ✓ ✓
Endothelial cell count measurement ✓§ ✓ ✓ ✓
Randomisation ✓
Treatment: standard care: Manual
Phacoemulsification Cataract Surgery
✓
Treatment: Intervention: Femtosecond
Laser-Assisted Phacoemulsification
Cataract Surgery
✓
Adverse event collection ✓ ✓†† ✓ ✓†† ✓
*Current glasses or unaided.
†UDVA: uncorrected distance visual acuity. All visual acuity measures will use the standard ETDRS logMAR chart at 4 metres.
‡CDVA: corrected distance visual acuity using subjective refraction result.
§Some patients will have these tests performed at the standard preassessment visit, depending on the site local procedure for surgical preassessment.
**The CSRI is a questionnaire for collecting retrospective information about study patients’ use of health and social care services, accommodation and living situation, income, employment and
benefits.17
††Patient reported complications only.
CDVA, corrected distance visual acuity; CSRI, Client Service Receipt Inventory; ETDRS, Early Treatment Diabetic Retinopathy Study; UDVA, uncorrected distance visual acuity.
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Requests for access to trial data will be considered,
and approved in writing where appropriate, after formal
application to the Trial Management Group/ Trial
Steering Group. Considerations for approving access are
documented in the Trial Management Group/Trial
Steering Committee Terms of Reference.
Statistical methods
The primary analysis will be conducted following the
intention-to-treat principle where all randomised
patients are analysed in their allocated group whether or
not they receive their randomised treatment. Baseline
characteristics will be summarised for each treatment
groups. Continuous data will be summarised using
means and SDs if data appear Gaussian, or medians and
IQRs. Binary data will be reported as frequencies and
percentages. All statistical tests will use a two-sided
p value of 0.05 unless otherwise speciﬁed. All CIs
presented will be 95% and two sided. A detailed statis-
tical analysis plan will be developed for approval by the
Trial Steering Committee and review by the
Independent Data Monitoring Committee and ﬁnalised
before the ﬁrst substantive statistical analysis.
The primary outcome is UDVA in the study eye
3 months after randomisation, measured in logMAR
using an ETDRS chart at a starting distance of 4 m.
Figure 1 Summary trial
participant pathways.
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A two-sided 95% CI for the mean difference in UDVA
between treatment groups will be estimated using regres-
sion analysis adjusting for baseline habitual logMAR
visual acuity and the randomisation stratiﬁers (treatment
centre, surgeon and whether or not patients have one
or both eyes eligible).
We will include trial site in our regression models as a
ﬁxed effect and surgeon as a random effect. If the
upper end of the 95% CI for the difference between
means does not cross the non-inferiority limit of 0.1
logMAR, then laser surgery will be regarded as non-
inferior. If the mean difference is negative and its 95%
CI lies wholly to the left of zero, then we can conclude
that laser surgery is superior to manual surgery. We will
perform sequential testing of the non-inferiority and
superiority hypotheses.
Secondary continuous outcomes such as UDVA at
12 months, CDVA and patient-reported Catquest-9SF11
will be analysed in a similar fashion. The percentage of
study eyes (and patients) experiencing adverse events
(eg, posterior capsule tears, dropped lens) in the two
groups will be compared using Fisher’s exact tests.
In addition regression analyses will be performed for
continuous outcomes such as CDVA at 12 months for
all operated eyes (ie, including the second eye for
patients having bilateral surgery), adjusting for baseline
habitual logMAR visual acuity, the randomisation strati-
ﬁers (centre and surgeon) and time since surgery,
including patient as a random effect. No additional
research visits are planned for patients having surgery
on both eyes.
Pearson’s correlation coefﬁcients (or Spearman’s rank
correlation coefﬁcients, depending on the distribution
of the data) will be used to assess the relationships
between continuous outcome measures.
Planned subgroup analyses will be conducted to inves-
tigate possible interactions between treatment effects
and whether or not surgery was required on both eyes,
with separate estimates and CIs being reported for such
patients. We will also investigate a possible interaction
between treatment effect and trial site as a prespeciﬁed
subgroup analysis.
Missing data
While there is no planned research visit between surgery
and the postoperative visit at 3 months, it is likely that
patients will attend standard NHS visits following
surgery. If data are missing for the primary end point
because patients do not attend for follow-up at
3 months, visual acuity data will be extracted from
patient records and inputted for the primary analysis. If
after retrieving the NHS records a substantial proportion
of primary outcome data remains incomplete, then
missing data will be dealt with using multiple imputation
by chained equations. Results will be combined using
Rubin’s rules. Data will be assumed to be missing at
random, in essence the data available for patients before
they drop out will be used to predict the end point.
The imputation will be performed following a prespeci-
ﬁed procedure and conducted separately for each trial
group. Reasons for missingness may be important and
these will be investigated using logistic regression of cov-
ariates on an indicator of missingness. Sensitivity analysis
will investigate the validity of the missing at random
assumption.
Economic analysis
We will undertake a detailed analysis of the costs and the
cost-utility of laser-assisted phacoemulsiﬁcation cataract
surgery compared with manual phacoemulsiﬁcation
cataract surgery (standard care). The analyses will
conform to accepted economic evaluation methods (eg,
NICE methods guidance). All costs will be assessed from
the perspective of the NHS and personal social services.
Secondary analysis will consider patient and societal
costs. We will estimate cost and cost-utility (1) for the
‘within-trial’ period, based on the clinical and
health-related quality of life results at baseline and
follow-up and (2) over the expected lifetime of the
patients. We have selected the EQ-5D-3L+vision bolt-on
question (EQ-5DV)12 as the most appropriate instru-
ment for use in this population.
Within-trial analysis
The units of outcome for the within-trial cost-
effectiveness analyses will be the incremental cost per
unit change in the uncorrected distance visual acuity
(UDVA) in the study eye and the incremental cost per
quality-adjusted life year (QALY) gained. QALYs will be
calculated based on the responses to the EQ-5DV col-
lected at baseline and follow-up. Patient-speciﬁc utility
proﬁles will be constructed assuming a linear change in
utility values measured using the EQ-5DV questionnaire
at baseline and 6-week, 3-month, 6-month and 12 month
follow-up time points. Utility estimates will be calculated
according to the area under the curve approach, adjust-
ing for baseline differences in patients in the trial arms
if necessary. Missing EQ-5DV and resource use data will
be addressed using appropriate statistical methods in
consultation with the trial statistician.
Model-based analysis
In the lifetime model, cost-effectiveness will be calcu-
lated in terms of the incremental cost per QALY gained.
A review of previous cost-effectiveness and cost-utility
analyses will be conducted to identify any existing mod-
elling work that may be drawn on for developing the
model structure and informing model parameters. The
speciﬁc details of the data required to populate the
model will be determined following the development of
the model structure. We will undertake deterministic
(one, two and multiway) and probabilistic sensitivity ana-
lysis, the latter assuming appropriate distributions and
parameter values that will also be used to construct cost-
effectiveness acceptability curves.
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Health economic analysis plan
All analyses will be undertaken within a Bayesian frame-
work. Methods for conducting economic evaluation
using clinical trial data will be applied following
O’Hagan and Stevens15 and O’Hagan et al.16 Monte
Carlo simulation methods will be used to construct a
cost-effectiveness acceptability curve, based on the
expected net beneﬁt statistic, to estimate the probability
that the intervention is cost-effective for a range of
values of societal willingness to pay per QALY. We will
also subject the results to extensive deterministic (one,
two and multiway) sensitivity analysis.
Cost components included in the analysis will consist
of (but not necessarily be limited to) the cost of surgery
for both arms of the trial, complications arising from
surgery, all relevant diagnostic investigations, revision
surgery where necessary, hospital length of stay, out-
patient attendances, hospital readmissions, primary care
contacts, A&E attendances and prescribed medications.
The volume of resource use for each cost component
will be measured by a patient completed questionnaire
and from medical records. Patients will be asked for
details of any health and social care resources used
during the study period, as well as out of pocket pay-
ments and the impact of their condition on their
employment. Unit costs will be taken from standard pub-
lished sources where possible. Where published unit
costs are not available site speciﬁc unit costs will be
obtained as required.
Trial oversight
Trial management team (TMT): this will assist with
developing the design, co-ordination and day-to-day
operational issues in the management of the trial,
including budget management.
Trial management group (TMG): this will assist with
developing the design, co-ordination and strategic man-
agement of the trial. The membership, frequency of
meetings, activity (including trial conduct and data
review) and authority will be covered in the TMG terms
of reference.
Independent Trial Steering Committee (TSC): is the
independent group responsible for oversight of the trial
in order to safeguard the interests of trial participants.
The TSC provides advice to the CI, CCTU, the funder
and sponsor on all aspects of the trial through its inde-
pendent Chair. The membership, frequency of meet-
ings, activity (including trial conduct and data review)
and authority will be covered in the UCL CCTU TSC
terms of reference.
Independent Data Monitoring Committee (IDMC):
will monitor adverse events and serious adverse events
during the trial to inform their recommendations to the
TSC. The IDMC will be responsible for safeguarding the
interests of all trial patients. The IDMC is independent
from the sponsor and funders. The membership, fre-
quency of meetings, activity (including trial conduct and
data review) and authority will be covered in the UCL
CCTU IDMC terms of reference.
Interim analyses
No formal interim analysis is planned, but reports con-
cerning patient safety and key efﬁcacy outcomes will be
prepared for regular review by the IDMC who may
request an interim analysis if a report raises concern.
The IDMC will also be asked to review all the assump-
tions used for the sample size calculation before the end
of recruitment.
Harms
Serious adverse events will be reported in accordance
with the guidance from the National Research Ethics
Service (NRES, http://www.nres.npsa.nhs.uk) which is a
subdivision of the National Patient Safety Agency
http://www.npsa.nhs.uk and Good Clinical Practice
(GCP).
Expected intraoperative complications for both arms
include all those common to phacoemulsiﬁcation cata-
ract surgery.3 These include anterior capsule tear, poster-
ior capsule tear with or without vitreous loss, choroidal
effusion/haemorrhage, IOL exchanged following inser-
tion, zonular dialysis, intraoperative pupil constriction
needing intervention and dropped lens fragments or
nucleus. Expected intraoperative complications speciﬁc-
ally for the laser-assisted arm are failure to dock to laser,
aborted or incomplete laser delivery, incomplete
capsulotomy identiﬁed in surgery requiring manual
completion and laser delivery to an inappropriate struc-
ture of eye.
Expected postoperative complications for both arms
are postoperative uveitis, endophthalmitis, macular
oedema, retinal tear or retinal detachment, elevated
intraocular pressure requiring treatment, medication
allergy or intolerance, corneal oedema, vitreous to
wound, other ocular surgery.
Details of any of the complications listed above will be
recorded on the case report forms and reported to the
Chief Investigator and the IDMC.
Auditing
Monitoring of this trial will ensure compliance with
GCP.
ETHICS AND DISSEMINATION
Ethical and safety considerations
The study will be conducted in accordance with GCP
guidelines and has received a favourable ethical opinion
from the NRES Committee London—City Road and
Hampstead (reference number: 14/LO/1937). Trial
investigators will ensure that the study (including any
approved amendments) is conducted in accordance
with the principles of the Declaration of Helsinki. All
protocol modiﬁcations will be disseminated to all rele-
vant parties.
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Dissemination plan
The results of the trial will be disseminated regardless of
the direction of effect. The trial will be reported in
accordance with the relevant CONSORT guidance.
Trial ﬁndings will be disseminated to all potential
beneﬁciaries of the research including patients, carers
and relatives and also doctors, advisory bodies and
healthcare Commissioners. This will take the form of
papers in high-impact open-access medical journals and
also presentations at national and international medical
conferences. Trial results will also be disseminated to the
trial patients in a one-page summary written in lay
language.
Authorship
Publications generated from the trial will be attributed
to the FACT TMG, which will consist of all those who
have wholeheartedly collaborated in the trial. The main
report will be drafted by the TMG, and the ﬁnal version
will be reviewed by the TSC before submission for publi-
cation. TMG members will be named and their afﬁlia-
tions listed in the main report. All publications will be in
compliance with the CCTU Publication Policy.
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